A
References
American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Publishing.
Araldi, D., L. F. Ferrari, and J. D. Levine. 2015. Repeated mu-opioid exposure induces a novel form of the hyperalgesic priming model for transition to chronic pain. Journal of Neuroscience 35(36):12502–12517.
Asiedu, M. N., G. Dussor, and T. J. Price. 2016. Targeting AMPK for the alleviation of pathological pain. In Cordero M., Viollet B. (eds.) AMP-Activated Protein Kinase. Experientia Supplementum 107:257–285. Springer International Publishing.
Bair, E., S. Gaynor, G. D. Slade, R. Ohrbach, R. B. Fillingim, J. D. Greenspan, R. Dubner, S. B. Smith, L. Diatchenko, and W. Maixner. 2016. Identification of clusters of individuals relevant to temporomandibular disorders and other chronic pain conditions: The OPPERA study. Pain 157(6):1266–1278.
Baliki, M. N., B. Petre, S. Torbey, K. M. Herrmann, L. Huang, T. J. Schnitzer, H. L. Fields, and A. V. Apkarian. 2012. Corticostriatal functional connectivity predicts transition to chronic back pain. Nature Neuroscience 15(8):1117–1119.
Basbaum, A. I., D. M. Bautista, G. Scherrer, and D. Julius. 2009. Cellular and molecular mechanisms of pain. Cell 139(2):267–284.
Brown, D. C. 2016. Resiniferatoxin: The evolution of the “molecular scalpel” for chronic pain relief. Pharmaceuticals 9(3):47.
CDC (Centers for Disease Control and Prevention). 2013. Notes from the field: Acetyl fentanyl overdose fatalities – Rhode Island, March–May 2013. Morbidity & Mortality Weekly Report (MMWR) 62(34):703–704.
CDC. 2017. Wide-ranging Online Data for Epidemiologic Research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics. http://wonder.cdc.gov (accessed February 27, 2018).
Chai, X., J. Xu, K. W. Johnson, T. Pottanat, R. Osborne, K. Cox, R. Benschop, J. L. Dage, K. Merchant, L. Adams, J. Talbot, and B. Miller. 2016. The development and validation of high sensitivity CGRP assays using meso scale
discovery and quanterix platforms. Paper presented at the 58th Annual Scientific Meeeting of the American Headache Society, San Diego, CA.
Chang, D. S., E. Hsu, D. G. Hottinger, and S. P. Cohen. 2016. Anti-nerve growth factor in pain management: Current evidence. Journal of Pain Research 9:373–383.
Chen, X., Y. Ba, L. Ma, X. Cai, Y. Yin, K. Wang, J. Guo, Y. Zhang, J. Chen, X. Guo, Q. Li, X. Li, W. Wang, Y. Zhang, J. Wang, X. Jiang, Y. Xiang, C. Xu, P. Zheng, J. Zhang, R. Li, H. Zhang, X. Shang, T. Gong, G. Ning, J. Wang, K. Zen, J. Zhang, and C. Y. Zhang. 2008. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research 18(10):997–1006.
Christensen, A. D., C. Haase, A. D. Cook, and J. A. Hamilton. 2016. K/BxN serum-transfer arthritis as a model for human inflammatory arthritis. Frontiers in Immunology 7:213.
Clauw, D. J., 2014. Fibromyalgia: a clinical review. Journal of the American Medical Association 311(15):1547–1555.
Copits, B. A., M. Y. Pullen, and R. W. Gereau. 2016. Spotlight on pain: Optogenetic approaches for interrogating somatosensory circuits. Pain 157(11):2424–2433.
Davis, K. D., H. Flor, H. T. Greely, G. D. Iannetti, S. Mackey, M. Ploner, A. Pustilnik, I. Tracey, R. D. Treede, and T. D. Wager. 2017. Brain imaging tests for chronic pain: Medical, legal and ethical issues and recommendations. Nature Reviews Neurology 13(10):624–638.
Deisseroth, K. 2011. Optogenetics. Nature Methods 8(1):26–29.
Diatchenko, L., G. D. Slade, A. G. Nackley, K. Bhalang, A. Sigurdsson, I. Belfer, D. Goldman, K. Xu, S. A. Shabalina, D. Shagin, M. B. Max, S. S. Makarov, and W. Maixner. 2005. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Human Molecular Genetics 14(1):135–143.
Douglas, S. R., B. B. Shenoda, R. A. Qureshi, A. Sacan, G. M. Alexander, M. Perreault, J. E. Barrett, E. Aradillas-Lopez, R. J. Schwartzman, and S. K. Ajit. 2015. Analgesic response to intravenous ketamine is linked to a circulating microRNA signature in female patients with complex regional pain syndrome. Journal of Pain 16(9):814–824.
Dowell, D., E. Arias, K. Kochanek, R. Anderson, G. P. Guy, Jr., J. L. Losby, and G. Baldwin. 2017. Contribution of opioid-involved poisoning to the change in life expectancy in the United States, 2000–2015. Journal of the American Medical Association 318(11):1065–1067.
Dowling, J., G. K. Isbister, C. M. Kirkpatrick, D. Naidoo, and A. Graudins. 2008. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Therapeutic Drug Monitoring 30(4):490–496.
Drenth, J. P., and S. G. Waxman. 2007. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. Journal of Clinical Investigation 117(12):3603–3609.
Duff, E. P., W. Vennart, R. G. Wise, M. A. Howard, R. E. Harris, M. Lee, K. Wartolowska, V. Wanigasekera, F. J. Wilson, M. Whitlock, I. Tracey, M. W. Woolrich, and S. M. Smith. 2015. Learning to identify CNS drug action and efficacy using multistudy fMRI data. Science Translational Medicine 7(274):274ra216.
Durham, P. L., and C. V. Vause. 2010. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs 24(7):539–548.
Edvinsson, L. 2001. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: Therapeutic implications. CNS Drugs 15(10):745–753.
Eijkelkamp, N., C. Steen-Louws, S. A. Hartgring, H. L. Willemen, J. Prado, F. P. Lafeber, C. J. Heijnen, C. E. Hack, J. A. van Roon, and A. Kavelaars. 2016. IL4-10 fusion protein is a novel drug to treat persistent inflammatory pain. Journal of Neuroscience 36(28):7353–7363.
Fitzcharles, M. A., P. A. Ste-Marie, and J. X. Pereira. 2013. Fibromyalgia: Evolving concepts over the past 2 decades. Canadian Medical Association Journal 185(13):E645–E651.
Freilinger, T., V. Anttila, B. de Vries, R. Malik, M. Kallela, G. M. Terwindt, P. Pozo-Rosich, B. Winsvold, D. R. Nyholt, W. P. van Oosterhout, V. Artto, U. Todt, E. Hamalainen, J. Fernandez-Morales, M. A. Louter, M. A. Kaunisto, J. Schoenen, O. Raitakari, T. Lehtimaki, M. Vila-Pueyo, H. Gobel, E. Wichmann, C. Sintas, A. G. Uitterlinden, A. Hofman, F. Rivadeneira, A. Heinze, E. Tronvik, C. M. van Duijn, J. Kaprio, B. Cormand, M. Wessman, R. R. Frants, T. Meitinger, B. Muller-Myhsok, J. A. Zwart, M. Farkkila, A. Macaya, M. D. Ferrari, C. Kubisch, A. Palotie, M. Dichgans, A. M. van den Maagdenberg, and International Headache Genetics Consortium. 2012. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nature Genetics 44(7):777–782.
Gewandter, J. S., R. H. Dworkin, D. C. Turk, J. T. Farrar, R. B. Fillingim, I. Gilron, J. D. Markman, A. L. Oaklander, M. J. Polydefkis, S. N. Raja, J. P. Robinson, C. J. Woolf, D. Ziegler, M. A. Ashburn, L. B. Burke, P. Cowan, S. Z. George, V. Goli, O. X. Graff, S. Iyengar, G. W. Jay, J. Katz, H. Kehlet, R. A. Kitt, E. A. Kopecky, R. Malamut, M. P. McDermott, P. Palmer, B. A. Rappaport, C. Rauschkolb, I. Steigerwald, J. Tobias, and G. A. Walco. 2015. Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain 156(7):1184–1197.
Goadsby, P. J., L. Edvinsson, and R. Ekman. 1990. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology 28(2):183–187.
Gorodetzky, C. W., S. L. Walsh, P. R. Martin, A. J. Saxon, K. L. Gullo, and K. Biswas. 2017. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug and Alcohol Dependence 176:79–88.
Grace, P. M., T. J. Fabisiak, S. M. Green-Fulgham, N. D. Anderson, K. A. Strand, A. J. Kwilasz, E. L. Galer, F. R. Walker, B. N. Greenwood, S. F. Maier, M. Fleshner, and L. R. Watkins. 2016. Prior voluntary wheel running attenuates neuropathic pain. Pain 157(9):2012–2023.
Greenwald, M., C. E. Johanson, J. Bueller, Y. Chang, D. E. Moody, M. Kilbourn, R. Koeppe, and J. K. Zubieta. 2007. Buprenorphine duration of action: Mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biological Psychiatry 61(1):101–110.
Hedegaard, H., M. Warner, and A. M. Miniño. 2017. Drug overdose deaths in the United States, 1999–2016. NCHS Data Brief, no. 294. Hyattsville, MD: CDC, National Center for Health Statistics.
Ho, T. W., M. D. Ferrari, D. W. Dodick, V. Galet, J. Kost, X. Fan, H. Leibensperger, S. Froman, C. Assaid, C. Lines, H. Koppen, and P. K. Winner. 2008. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet 372(9656):2115–2123.
Ho, T. W., K. M. Connor, Y. Zhang, E. Pearlman, J. Koppenhaver, X. Fan, C. Lines, L. Edvinsson, P. J. Goadsby, and D. Michelson. 2014. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 83(11):958–966.
Indo, Y., M. Tsuruta, Y. Hayashida, M. A. Karim, K. Ohta, T. Kawano, H. Mitsubuchi, H. Tonoki, Y. Awaya, and I. Matsuda. 1996. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nature Genetics 13(4):485–488.
IOM (Institute of Medicine). 2011. Relieving pain in America: A blueprint for transforming prevention, care, education, and research. Washington, DC: The National Academies Press.
Joseph, E. K., D. B. Reichling, and J. D. Levine. 2010. Shared mechanisms for opioid tolerance and a transition to chronic pain. Journal of Neuroscience 30(13):4660–4666.
Kakko, J., K. D. Svanborg, M. J. Kreek, and M. Heilig. 2003. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 361(9358):662–668.
Kandasamy, R., and T. J. Price. 2015. The pharmacology of nociceptor priming. In Pain Control (pp. 15–37). Springer Berlin Heidelberg.
Kehlet, H., T. S. Jensen, and C. J. Woolf. 2006. Persistent postsurgical pain: Risk factors and prevention. Lancet 367(9522):1618–1625.
Kielbasa, W., T. Quinlan, R. Bell, B. Miller, and V. Skljarevski. 2016. Pharmacokinetic and pharmacodynamic modeling of LY2951742, a calcitonin gene-related peptide antibody, in migraine patients. Neurology 86(16 Suppl.):P6.091.
Kim, J. Y., D. V. Tillu, T. L. Quinn, G. L. Mejia, A. Shy, M. N. Asiedu, E. Murad, A. P. Schumann, S. K. Totsch, R. E. Sorge, P. W. Mantyh, G. Dussor, and T. J. Price. 2015. Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism. Journal of Neuroscience 35(16):6307–6317.
Krieter, P., N. Chiang, S. Gyaw, P. Skolnick, R. Crystal, F. Keegan, J. Aker, M. Beck, and J. Harris. 2016. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. Journal of Clinical Pharmacology 56(10):1243–1253.
Krukowski, K., N. Eijkelkamp, G. Laumet, C. E. Hack, Y. Li, P. M. Dougherty, C. J. Heijnen, and A. Kavelaars. 2016. CD8+ T cells and endogenous IL-10 are required for resolution of chemotherapy-induced neuropathic pain. Journal of Neuroscience 36(43):11074–11083.
Kutch, J. J., E. Ichesco, J. P. Hampson, J. S. Labus, M. A. Farmer, K. T. Martucci, T. J. Ness, G. Deutsch, A. V. Apkarian, S. C. Mackey, D. J. Klumpp, A. J. Schaeffer, L. V. Rodriguez, K. J. Kreder, D. Buchwald, G. L. Andriole, H. H. Lai, C. Mullins, J. W. Kusek, J. R. Landis, E. A. Mayer, J. Q. Clemens, D. J. Clauw, R. E. Harris, and M. R. Network. 2017. Brain signature and functional impact of centralized pain: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) network study. Pain 158(10):1979–1991.
Mantyh, P. W., M. Koltzenburg, L. M. Mendell, L. Tive, and D. L. Shelton. 2011. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology 115(1):189–204.
Martin, L. J., M. H. Piltonen, J. Gauthier, M. Convertino, E. L. Acland, N. V. Dokholyan, J. S. Mogil, L. Diatchenko, and W. Maixner. 2015. Differences in the antinociceptive effects and binding properties of propranolol and bupranolol enantiomers. The Journal of Pain 16(12):1321–1333.
Martin, L. J., S. B. Smith, A. Khoutorsky, C. A. Magnussen, A. Samoshkin, R. E. Sorge, C. Cho, N. Yosefpour, S. Sivaselvachandran, S. Tohyama, T. Cole, T. M. Khuong, E. Mir, D. G. Gibson, J. S. Wieskopf, S. G. Sotocinal, J. S. Austin, C. B. Meloto, J. H. Gitt, C. Gkogkas, N. Sonenberg, J. D. Greenspan, R. B. Fillingim, R. Ohrbach, G. D. Slade, C. Knott, R. Dubner, A. G. Nackley, A. Ribeiro-da-Silva, G. G. Neely, W. Maixner, D. V. Zaykin, J. S. Mogil, and L. Diatchenko. 2017. Epiregulin and EGFR interactions are involved in pain processing. Journal of Clinical Investigation 127(9):3353–3366.
McDonald, M. K., Y. Tian, R. A. Qureshi, M. Gormley, A. Ertel, R. Gao, E. Aradillas Lopez, G. M. Alexander, A. Sacan, P. Fortina, and S. K. Ajit. 2014. Functional significance of macrophage-derived exosomes in inflammation and pain. Pain 155(8):1527–1539.
McDonald, M. K., S. Ramanathan, A. Touati, Y. Zhou, R. U. Thanawala, G. M. Alexander, A. Sacan, and S. K. Ajit. 2016. Regulation of pro-inflammatory genes by the circulating microRNA hsa-miR-939. Scientific Reports 6:30976.
Megat, S., S. Shiers, J. K. Moy, P. Barragan-Iglesias, G. Pradhan, R. P. Seal, G. Dussor, and T. J. Price. 2017. A critical role for dopamine D5 receptors in pain chronicity in male mice. Journal of Neuroscience 38(2):379–397.
Miller, R. E., J. A. Block, and A. M. Malfait. 2017. Nerve growth factor blockade for the management of osteoarthritis pain: What can we learn from clinical trials and preclinical models? Current Opinion Rheumatology 29(1):110–118.
Mitchell, P. S., R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanyan, A. Peterson, J. Noteboom, K. C. O’Briant, A. Allen, D. W. Lin, N. Urban, C. W. Drescher, B. S. Knudsen, D. L. Stirewalt, R. Gentleman, R. L. Vessella, P. S. Nelson, D. B. Martin, and M. Tewari. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 105(30):10513–10518.
Nackley, A. G., S. A. Shabalina, I. E. Tchivileva, K. Satterfield, O. Korchynskyi, S. S. Makarov, W. Maixner, and L. Diatchenko. 2006. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314(5807):1930–1933.
Nackley, A. G., K. S. Tan, K. Fecho, P. Flood, L. Diatchenko, and W. Maixner. 2007. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 128(3):199–208.
Nahin, R. L. 2015. Estimates of pain prevalence and severity in adults: United States, 2012. The Journal of Pain 16(8):769–780.
NASEM (National Academies of Sciences, Engineering, and Medicine). 2017. Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use. Washington, DC: The National Academies Press.
Nasser, A. F., M. K. Greenwald, B. Vince, P. J. Fudala, P. Twumasi-Ankrah, Y. Liu, J. P. Jones, 3rd, and C. Heidbreder. 2016. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. Journal of Clinical Psychopharmacology 36(1):18–26.
NIH (National Insitutes of Health). 2017. Federal Pain Research Stategy. The Interagency Pain Research Coordinating Committee. https://iprcc.nih.gov/sites/default/files/FPRS_Research_Recommendations_Final_508C.pdf (accessed December 15, 2017).
Olanow, C. W., R. T. Bartus, L. A. Volpicelli-Daley, and J. H. Kordower. 2015. Trophic factors for Parkinson’s disease: To live or let die. Movement Disorders 30(13):1715–1724.
Olesen, J., H. C. Diener, I. W. Husstedt, P. J. Goadsby, D. Hall, U. Meier, S. Pollentier, and L. M. Lesko. 2004. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New England Journal of Medicine 350(11):1104–1110.
Orlova, I. A., G. M. Alexander, R. A. Qureshi, A. Sacan, A. Graziano, J. E. Barrett, R. J. Schwartzman, and S. K. Ajit. 2011. MicroRNA modulation in complex regional pain syndrome. Journal of Translational Medicine 9:195.
Park, S. I., D. S. Brenner, G. Shin, C. D. Morgan, B. A. Copits, H. U. Chung, M. Y. Pullen, K. N. Noh, S. Davidson, S. J. Oh, J. Yoon, K. I. Jang, V. K. Samineni, M. Norman, J. G. Grajales-Reyes, S. K. Vogt, S. S. Sundaram, K. M. Wilson, J. S. Ha, R. Xu, T. Pan, T. I. Kim, Y. Huang, M. C. Montana, J. P. Golden, M. R. Bruchas, R. W. Gereau, and J. A. Rogers. 2015. Soft, stretchable, fully implantable miniaturized optoelectronic systems for wireless optogenetics. Nature Biotechnology 33(12):1280–1286.
Patel, S. P., and R. Kurzrock. 2015. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Molecular Cancer Therapeutics 14(4):847–856.
Pravetoni, M., P. R. Pentel, D. N. Potter, E. H. Chartoff, L. Tally, and M. G. LeSage. 2014. Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PLoS ONE 9(7):e101807.
Qureshi, R. A., Y. Tian, M. K. McDonald, K. E. Capasso, S. R. Douglas, R. Gao, I. A. Orlova, J. E. Barrett, S. K. Ajit, and A. Sacan. 2016. Circulating microRNA signatures in rodent models of pain. Molecular Neurobiology 53(5):3416–3427.
Reichling, D. B., and J. D. Levine. 2009. Critical role of nociceptor plasticity in chronic pain. Trends in Neuroscience 32(12):611–618.
Research!America. 2013. A Research!America poll of U.S. adults conducted in partnership with Zogby Analytics in March, 2013.https://www.researchamerica.org/sites/default/files/uploads/March2013painaddiction.pdf (accessed February 26, 2018).
Rudd, R. A., P. Seth, F. David, and L. Scholl. 2016. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. Morbidity and Mortality Weekly Report 65(5051):1445–1452.
Schumann, H., T. Erickson, T. M. Thompson, J. L. Zautcke, and J. S. Denton. 2008. Fentanyl epidemic in Chicago, Illinois, and surrounding Cook County. Clinical Toxicology 46:501–506.
Shabalina, S. A., D. V. Zaykin, P. Gris, A. Y. Ogurtsov, J. Gauthier, K. Shibata, I. E. Tchivileva, I. Belfer, B. Mishra, C. Kiselycznyk, M. R. Wallace, R. Staud, N. A. Spiridonov, M. B. Max, D. Goldman, R. B. Fillingim, W. Maixner, and L. Diatchenko. 2009. Expansion of the human mu-opioid receptor gene architecture: Novel functional variants. Human Molecular Genetics 18(6):1037–1051.
Sinclair, S. R., S. A. Kane, B. J. Van der Schueren, A. Xiao, K. J. Willson, J. Boyle, I. de Lepeleire, Y. Xu, L. Hickey, W. S. Denney, C. C. Li, J. Palcza, F. H. Vanmolkot, M. Depre, A. Van Hecken, M. G. Murphy, T. W. Ho, and J. N. de Hoon. 2010. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). British Journal of Clinical Pharmacology 69(1):15–22.
Sluka, K. A., and D. J. Clauw. 2016. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience 338:114–129.
Taylor, B. K., and G. Corder. 2014. Endogenous analgesia, dependence, and latent pain sensitization. Current Topics in Behavioral Neurosciences 20:283–325.
Tchivileva, I. E., P. F. Lim, S. B. Smith, G. D. Slade, L. Diatchenko, S. A. McLean, and W. Maixner. 2010. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: A randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenetic Genomics 20(4):239–248.
Terplan, M. 2017. Women and the opioid crisis: Historical context and public health solutions. Fertility and Sterility 108(2):195–199.
Tso, A. R., and P. J. Goadsby. 2017. Anti-CGRP monoclonal antibodies: The next era of migraine prevention? Current Treatment Options in Neurology 19(8):27.
Tuttle, A. H., S. Tohyama, T. Ramsay, J. Kimmelman, P. Schweinhardt, G. J. Bennett, and J. S. Mogil. 2015. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain 156(12):2616–2626.
Volkow, N. D., and F. S. Collins. 2017. The role of science in addressing the opioid crisis. New England Journal of Medicine 377(4):391–394.
Wager, T. D., L. Y. Atlas, M. A. Lindquist, M. Roy, C. W. Woo, and E. Kross. 2013. An fMRI-based neurologic signature of physical pain. New England Journal of Medicine 368(15):1388–1397.
Walsh, S. L., S. D. Comer, M. R. Lofwall, B. Vince, N. Levy-Cooperman, D. Kelsh, M. A. Coe, J. D. Jones, P. A. Nuzzo, F. Tiberg, B. Sheldon, and S. Kim. 2017. Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: A randomized clinical trial. JAMA Psychiatry 74(9):894–902.
Woller, S. A., K. A. Eddinger, M. Corr, and T. L. Yaksh. 2017. An overview of pathways encoding nociception. Clinical and Experimental Rheumatology (35 Suppl.) 107(5):40–46.
Woo, C. W., M. Roy, J. T. Buhle, and T. D. Wager. 2015. Distinct brain systems mediate the effects of nociceptive input and self-regulation on pain. PLoS Biology 13(1):e1002036.
Xu, Z. Z., L. Zhang, T. Liu, J. Y. Park, T. Berta, R. Yang, C. N. Serhan, and R. R. Ji. 2010. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nature Medicine 16(5):592–597.
Zorina-Lichtenwalter, K., C. B. Meloto, S. Khoury, and L. Diatchenko. 2016. Genetic predictors of human chronic pain conditions. Neuroscience 338:36–62.
